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In the current issue of the Korean Journal of Anesthesiology, 
two articles demonstrate that N-methyl-D-aspartate (NMDA) 
receptor antagonists prevent remifentanil-induced hyper-
algesia. Hong et al. [1] showed that continuous infusion of 
low dose ketamine decreased early postoperative pain score 
and analgesic requirement in patients with sevoflurane and 
remi  fentanil anesthesia. Lee et al. [2] also found that wound 
infiltration of magnesium sulfate decreased opioid consump-
tion and reduced opioid-induced hyperalgesia (OIH). Ketamine 
is a non-competitive and magnesium is a physiologic NMDA 
receptor blocker. NMDA receptor blockers might prevent 
central sensitization by inhibiting activation of excitatory amino 
acids such as glutamate on NMDA receptors.
The administration of opioids is often related to the develop-
ment of paradoxical and pathologic pain termed as OIH and 
tolerance. Tolerance is a pharmacologic concept which defined 
as a progressive decrease in response to a drug [3]. A variety of 
drugs, not a specific to the opioid family, can cause tolerance. 
Tolerance can be overcome by increasing dose of the drug. 
OIH is a paradoxical response to an opioid, whereby a patient 
receiving opioid for the treatment of pain might actually have 
an increase in pain perception to certain painful stimuli. OIH 
may complicate the clinical course of a patient who receives 
opioid treatment for pain control. The pronociception may 
occur in the same area as the underlying pain or away from the 
original site of the pain. The nature of pain often is associated 
with neuropathic pain such as hyperalgesia or allodynia. 
OIH is different from tolerance and it cannot be overcome by 
increasing dose of the drug because OIH is a pain sensitization 
of nerve system induced by the drug. Pain is aggravated with 
increased opioid dosage and improved by reducing or cessation 
of the drug. Therefore, OIH is clinical challenge to acute and 
chronic pain treatment. 
Although there has been a controversy about its clinical 
implication, substantial evidence has been reported to support 
the development of OIH in experimental and clinical studies. 
There are several proposed mechanisms for OIH. Both central 
and peripheral sensitization to pain occurs in the nervous 
system. Central sensitization in the spinal cord involves 
the glutamate receptor, the NMDA receptor. The excitatory 
neurotransmitter plays a key role in the development of OIH. 
Spinal dynorphin levels were increased with continuous 
infusions of opioids and increased dynorphin levels lead to the 
release of spinal excitatory neuropeptides [4]. Neurons within 
the descending pathway in the spinal cord may facilitate spinal 
nocioceptive processing [5]. In cultured rat spinal neurons, 
remifentanil induce persistent increases in NMDA responses 
which is inducible by δ-opioid receptor activation with a 
dynorphin agonist [6]. Gabapentin and pregabalin, which have 
a presynaptic effect on glutamate release, prevent OIH in rats 
and humans [7,8]. Also, these pro-nociceptive processes were 
facilitated in the spinal cord by increasing the synthesis of 
excitatory neuropeptides including 5-HT3, cholecystokinin, and 
substance P. Spinal dynorphin and facilitation of descending 
pathway in the spinal cord play important roles in OIH. 
Peripheral receptors also play a role in OIH, with evidence that 
the transient receptor potential vanilloid receptor 1 (TRPV1) is 
important in the development of hyperalgesia [9,10]. A TRPV1 
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antagonist was found to reverse OIH, along with increasing 
TRPV1 receptors in the dorsal root ganglia and increasing the 
response to capsaicin [11]. Although OIH is different from 
tolerance, OIH (sensitization) and opioid-induced tolerance 
may share common mechanisms in part, which mediated 
through activation of the central glutamatergic system [12]. 
Why some patients suffer from OIH while others on even larger 
doses of opioids do not? Which factors influence the incidence 
of OIH? Both opioid dose and duration of treatment seem to be 
important factors. Genetic factors are also likely to play a role in 
susceptibility to OIH. 
Remifentanil is a short-acting synthetic mu-opioid agonist. 
Intraoperative remifentanil infusion is increasing in clinical 
practice because remifentanil is rapidly degraded with a 
short half-life. Although the incidence of OIH and tolerance 
after opioid treatment of pain remains unknown, it seems to 
occur more frequently with the administration of the short-
acting opioid remifentanil [13-15]. In clinical practice, patient 
receiving intraoperative remifentanil infusion may have more 
severe postoperative pain and increased analgesic requirement. 
In recent study, Shin et al. [16] demonstrated 4 ng/ml of 
effect site concentration of remifentanil infusion increase 
postoperative cumulative morphine consumption compare 
to 1 ng/ml (38.6 vs 31.5 mg) after breast cancer surgery. Lee et 
al. [2] in the Korean Journal of Anesthesiology present that the 
time of first postoperative analgesic requirement is shorter in 
remifentanil infusion group (34 min) than desflurane group 
(61 min). Jo et al. [8] showed remifentanil infusion group (228 
μg) require more fentanyl dose than control group (134 μg) 
for titration of pain in postanesthesia care unit. These studies 
report that remifentanil infusion groups have higher pain scores 
at postoperative period. The studies raise a question whether 
increased postoperative analgesic requirement and pain score 
could be associated with OIH, tolerance or both.
If decreased or lack of efficacy of opioids in the postoperative 
period has been seen as a result of OIH, a major dilemma that 
anesthesiologists face. Because most anesthesiologists use 
opioids as the first line for postoperative pain control, it may 
be more prudent to use intraoperative remifentanil infusion. 
Although tolerance and OIH may share common mechanisms, 
it is challenging to distinguish between them since the 
treatment of each is quite different. OIH typically produces 
diffuse pain, less defined in quality, which extends to other 
areas from the preexisting pain. Schmidt et al. [17] studied 
patients with high dose (0.4 μg/kg/min) or low dose (0.1 μg/
kg/min) of remifentanil, and assessed postoperative pain at the 
surgical site and at other sites compared during preoperative 
baseline, at 30 and 90 min after cessation of remifentanil 
infusion. The patients who received high dose remifentanil 
anesthesia showed the development of hyperalgesia to painful 
pressure. In a double-blind randomized controlled trial of 
patients undergoing major abdominal surgery, results showed 
only transient higher pain scores in remifentanil group for up 
to 2 h after surgery [18]. Konopka and Wijhe [19] found that 
higher early postoperative pain score and subsequent greater 
demand of opioids after remifentanil-based anesthesia could be 
attributed to tolerance, and the greater requirement for opioids 
at a later recovery stage could be associated with OIH. Although 
there are many experimental and clinical studies on OIH, 
further research is needed to define the clinical problem and 
neurobiological mechanisms including central and peripheral 
neural pathways. Furthermore, clinical studies need to be 
designed to differentiate between tolerance and OIH in order 
to develop clinical strategies to reduce OIH in the patients with 
intraoperative remifentanil in infusion.
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